« Previous article
Hop-Latent Viroid De...

6th July 2021  Product update: rapidvirology staff writer

Molecular Assay to Quantify Human Cytomegalovirus Receives CE-mark


Hologic, Inc. has received CE marking for its new Aptima® CMV Quant assay in Europe. This assay, which quantifies the viral load of human cytomegalovirus (CMV), is intended for use to aid in the diagnosis and management of solid-organ transplant patients and hematopoietic stem cell transplant patients. This in vitro nucleic acid amplification test (NAAT) uses real-time transcription-mediated amplification (TMA) technology on the fully automated Panther® system and can be used with human plasma and whole blood samples.

“Immunocompromised patients are vulnerable to a range of infections, with CMV a frequent complication, and healthcare providers need to quantify and monitor CMV accurately,” said Jan Verstreken, group president, International. “Our Aptima CMV Quant assay is the first in a new line of Hologic assays for transplant patients and demonstrates our commitment to our laboratory partners to expand our molecular diagnostics business into new segments.”

Human CMV is a common DNA virus that belongs to the herpes family. Its prevalence in the population ranges from 45 to 100% worldwide. CMV infections are typically mild or asymptomatic in people with normal immune systems. However, in immunocompromised people such as transplant recipients, CMV is a common cause of morbidity and mortality. CMV, like other herpes viruses, may cause a lifelong latent infection that can sporadically reactivate. In transplant recipients, transfer of latent CMV in the graft or reactivation of latent CMV infection in the host may result in widespread viral replication and dissemination to multiple organs, which is often life-threatening.

As higher viral loads generally correlate to an increased risk of CMV disease, it is crucial that CMV levels are quantitated in transplant patients, in conjunction with monitoring clinical presentation and other laboratory markers. Recent guidelines recommend at least weekly monitoring of CMV viral load post-transplant to guide decisions about starting anti-CMV therapy as well as to monitor response to therapy. Quantitative nucleic acid amplification testing is the preferred method as it is both rapid and sensitive.

For further details on Aptima assays, please use the 'Request Information' button provided below or visit www.hologic.com


    

Tags:

Date Published: 6th July 2021

Source article link: View

Note: This content has been edited by a rapidvirology.com staff writer for style and content.


View full company details